Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes

被引：70

作者：

Levy, Mark L. ^{[1
]}

Carroll, Will ^{[2
]}

Izquierdo Alonso, Jose L. ^{[3
]}

Keller, Claus ^{[4
]}

Lavorini, Federico ^{[5
]}

Lehtimaki, Lauri ^{[6
]}

机构：

[1] Kenton Bridge Med Ctr, London, England

[2] Univ Hosp North Midlands NHS Trust, Dept Paediat, Stoke On Trent, Staffs, England

[3] Univ Alcala, Guadalajara Univ Hosp, Serv Pneumol, Madrid, Spain

[4] Practice Pneumol Allergol & Work Med, Frankfurt, Germany

[5] Univ Florence, Dept Clin & Expt Med, Sect Resp Med, Florence, Italy

[6] Tampere Univ, Tampere Univ Hosp, Allergy Ctr, Fac Med & Hlth Technol, Tampere, Finland

来源：

ADVANCES IN THERAPY | 2019年 / 36卷 / 10期

关键词：

Adherence; Asthma; COPD; Device resistance; Dry powder inhalers; Respiratory; INSPIRATORY FLOW-RATE; IN-VITRO; BUDESONIDE-FORMOTEROL; FINE LACTOSE; MEDICATION ADHERENCE; REPEATED INSTRUCTION; INHALATION; ASTHMA; DRUG; EASYHALER(R);

D O I：

10.1007/s12325-019-01066-6

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Inhalable medications for patients with asthma and chronic obstructive pulmonary disease (COPD) can be confusing even for health care professionals because of the multitude of available devices each with different operating principles. Dry powder inhalers (DPI) are a valuable option for almost all of the patients with asthma or COPD. Based on recorded patient inspiratory profiles, the peak inspiratory flow requirement of 30 L min(-1) of high-resistance devices does not usually pose any practical limitations for the patients. Suboptimal adherence and errors in device handling are common and require continuous checking and patient education in order to avoid these pitfalls of all inhalation therapy. The aim of this opinion paper is to describe the working principles of DPIs and to summarise their key properties in order to help prescribing the correct inhaler for each patient. Funding: Orion Pharma.

引用

页码：2547 / 2557

页数：11

共 65 条

[1] Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler [J].